scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1050379653 |
P356 | DOI | 10.1186/1745-6215-15-201 |
P932 | PMC publication ID | 4055939 |
P698 | PubMed publication ID | 24888356 |
P5875 | ResearchGate publication ID | 262840335 |
P50 | author | Shawn D. Aaron | Q41542409 |
Mohsen Sadatsafavi | Q57326502 | ||
Stirling Bryan | Q93033882 | ||
P2093 | author name string | Carlo Marra | |
P2860 | cites work | Modelling in economic evaluation: an unavoidable fact of life | Q28243908 |
A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. | Q30572097 | ||
Bayesian cost-effectiveness analysis from clinical trial data | Q30637667 | ||
Assessing the appropriateness of combining economic data from multinational clinical trials | Q30802399 | ||
Multiple imputation: a primer | Q33646777 | ||
Modelling in health economic evaluation. What is its place? What is its value? | Q34025535 | ||
The use of beta-agonists and the risk of death and near death from asthma | Q34241868 | ||
Introducing economic and quality of life measurements into clinical studies | Q34329579 | ||
Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach | Q35674633 | ||
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report | Q36263674 | ||
Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
Review of statistical methods for analysing healthcare resources and costs | Q37783588 | ||
Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis | Q37864538 | ||
Whither trial-based economic evaluation for health care decision making? | Q40349299 | ||
The interpretation of random-effects meta-analysis in decision models. | Q40373458 | ||
Hindsight Bias | Q40744098 | ||
Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. | Q41585693 | ||
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial | Q42612610 | ||
The Canadian Optimal Therapy of COPD Trial: design, organization and patient recruitment | Q45196251 | ||
Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. | Q45915556 | ||
Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. | Q46487220 | ||
Bayesian estimation of cost-effectiveness: an importance-sampling approach | Q47249565 | ||
Representing uncertainty: the role of cost-effectiveness acceptability curves | Q47573256 | ||
Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. | Q50499409 | ||
A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes. | Q52064637 | ||
A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty. | Q52070390 | ||
Bayesian estimation of cost-effectiveness ratios from clinical trials. | Q52213535 | ||
Confidence intervals for cost-effectiveness ratios: a comparison of four methods. | Q52265193 | ||
Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia | Q80076108 | ||
How sensitive are cost-effectiveness analyses to choice of parametric distributions? | Q80977056 | ||
Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report | Q84870284 | ||
P304 | page(s) | 201 | |
P577 | publication date | 2014-06-03 | |
P1433 | published in | Trials | Q7840023 |
P1476 | title | Incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods | |
P478 | volume | 15 |
Search more.